Eye Institute Locks Doors for Secret Grant Huddles
Published Date: 3/17/2025
Notice
Summary
The National Eye Institute is holding several closed virtual meetings in April 2025 to review and decide on important vision research grant applications. These meetings protect private info and trade secrets while helping decide who gets funding to advance eye health. If you’re involved in vision research grants, these dates are key for your funding chances!
Analyzed Economic Effects
8 provisions identified: 8 benefits, 0 costs, 0 mixed.
SBIR/STTR Small Business Review Dates
If you applied for Small Business Innovation Research (SBIR) or Small Business Technology Transfer (STTR) grants, your applications will be reviewed virtually on April 29–30, 2025 from 9:00 a.m. to 1:00 p.m. each day. These review meetings decide which small business proposals move forward for funding consideration.
Center Core (P30) Grant Review Date
If you applied for a Center Core Grant for Vision Research (P30), your application will be reviewed on April 1, 2025 in a virtual meeting from 9:30 a.m. to 3:00 p.m. at the National Eye Institute review panel.
Clinical Trial Grant Review Date
If you applied for a Clinical Trial grant, your application will be reviewed on April 25, 2025 in a virtual meeting from 12:00 p.m. to 4:30 p.m. by the National Eye Institute review panel.
Mentored Clinician Scientist (K08/K23) Review Date
If you applied for a Mentored Clinician Scientist career award (K08 or K23), your application will be reviewed on April 28, 2025 in a virtual meeting from 1:00 p.m. to 5:30 p.m.
Individual Pathway to Independence (K99) Review Date
If you submitted an Individual Pathway to Independence (K99) application, it will be reviewed on May 1, 2025 in a virtual meeting from 10:00 a.m. to 3:00 p.m. by the National Eye Institute panel.
Closed Reviews Protect Applicant Privacy
The National Eye Institute will close these meetings to the public under 5 U.S.C. 552b(c)(4) and 552b(c)(6) because grant applications could reveal confidential trade secrets or personal information. This means your grant application materials and personal details about people named in applications will be kept confidential during the review process.
Conference (R13) Grant Review Date
If you applied for a Conference Grant (R13), your application will be reviewed on April 11, 2025 in a virtual meeting from 12:00 p.m. to 4:00 p.m. by the National Eye Institute review panel.
Secondary Data Analysis (R21) Review Date
If you submitted a Secondary Data Analysis (R21) application, it will be reviewed on April 23, 2025 in a virtual meeting from 12:00 p.m. to 4:30 p.m. by the National Eye Institute panel.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-15565, Proposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
2026-14966, Government-Owned Inventions; Availability for Licensing
The National Institutes of Health is offering a new Ebola vaccine invention for companies to license and develop quickly. This vaccine targets the Bundibugyo virus and promises fast and lasting protection, helping stop outbreaks in Central Africa. Businesses interested in licensing should act soon to bring this life-saving tech to market and can contact NIH for details.
Previous / Next Documents
Previous: 2025-04144, National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting
The National Institute of Allergy and Infectious Diseases is holding a closed meeting from April 3-7, 2025, to review special grant applications about immunobiology and xenotransplantation. This meeting affects researchers applying for these grants and keeps sensitive info private. No public access or money changes are involved, but important funding decisions will be made behind the scenes.
Next: 2025-04146, Pacific Fishery Management Council; Public Meeting
The Pacific Fishery Management Council is holding online meetings with their Groundfish teams to plan for the big April 2025 fishing rules. Fishermen, seafood businesses, and ocean lovers should pay attention because these talks could change how groundfish are managed, affecting fishing limits and seasons. The meetings are open to everyone and help shape fair and smart fishing rules that balance the ocean’s health and the fishing economy.